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H eart disease is the cause of significant morbidity and mortality in the United States, with estimates of ≈800 000 new acute coronary events each year and accounts for a substantial proportion of the national healthcare expenditure. 1, 2 The cellular events after a myocardial infarction (MI) result in inadequate microvascular perfusion that causes a change in the composition of the extracellular matrix (ECM), with regional alterations in levels of matrix metalloproteinase (MMP) and tissue inhibitors of metalloproteinase (TIMP). These pathophysiological changes result in hypocontractile scar formation, myocyte apoptosis, and progressive ventricular dilatation. 3 The differential MMP/TIMP ratio leads to deleterious remodeling from proteolytic degradation of the ECM occurring over time. This increases the stress-strain relationship of ventricular myocytes and leads to inefficient contractility, infarct spreading, and ultimately heart failure. [4] [5] [6] [7] [8] [9] When current treatments for coronary artery disease fail, they usually do so because microvascular perfusion is not adequately restored-a critical, independent predictor of ventricular remodeling, reinfarction, heart failure, and death. 10 Inadequate microvascular perfusion also plays an important role in the progression to heart failure after MI. 10 To this end, many groups have experimented with various cell delivery and cytokine treatment regimens in an attempt to stimulate angiogenesis, with varying degrees of success. [11] [12] [13] [14] One such cytokine, stromal cell-derived factor 1α (SDF-1), is a key regulator in hematopoietic stem cell trafficking between the bone marrow and peripheral circulation and effectively localizes endothelial progenitor cells (EPCs) to areas of ischemia. [15] [16] [17] [18] SDF-1 is part of the C-X-C chemokine family, causing stem cell migration through interaction with the 7 transmembrane domain G protein-coupled receptor CXCR 4. After MI, cardiac secretion of SDF-1 is insufficiently robust to mobilize a sufficient population of EPCs to affect meaningful changes in perfusion. However, supraphysiologic doses of intramyocardial SDF-1 have been shown by our group and others to increase vasculogenesis, decrease cardiac myocyte apoptosis, increase cardiac myocyte survival, and preserve ventricular geometry. [19] [20] [21] [22] [23] [24] [25] Despite the reported beneficial effects of recombinant SDF-1 after an ischemic insult, it has some limitations. SDF-1 is broken down by multiple peptidases (CD26/DPP-IV) and requires Escherichia coli for production, a process that is inefficient and expensive. Recently, we have designed a biochemically modified, synthetic version of SDF-1, which we named engineered stromal cell-derived factor 1α analog (ESA), to overcome these hurdles, and have shown it to be effective in a small animal model of MI. [26] [27] [28] [29] [30] [31] In the current study, we hypothesized that intramyocardial delivery of ESA in a translational ovine model of MI would result in chemotaxis of EPCs, increased microrevascularization, limited ventricular remodeling, and improved regional and global ventricular function.
Methods
All experiments pertaining to this investigation conformed to the Guide for the Care and Use of Laboratory Animals, published by the US National Institutes of Health (Eighth Edition, 2011). The protocol was approved by the Institutional Animal Use and Care Committee of the University of Pennsylvania (protocol number 803430).
Custom Peptide Synthesis
We have previously reported on the design and synthesis of ESA. 27 Briefly, to minimize the profile of the peptide, the CXCR4 receptor binding N-terminus and the molecular stabilizing C-terminus were preserved, whereas the central β-pleated sheet was deleted. Using computational modeling, it was determined that a 2-proline residue linker joining this modified sequence would durably retain a 3-dimensional (3D) protein configuration similar to the native SDF-1 (Online Figure I ). The engineered protein was then synthesized using solid-phase peptide synthesis, where the N α-amino acids were incorporated into the peptide in a stepwise fashion while the C-terminal end was attached to a solid support matrix.
Endothelial Progenitor Cell Chemotaxis
Bone marrow mononuclear cells were isolated from the long bones of adult male Dorset sheep by density centrifugation with Histopaque 1083 (Sigma-Aldrich), plated on vitronectin-coated dishes, and cultured in endothelial basal medium 2 supplemented with EGM-2 SingleQuot (Lonza) containing human epidermal growth factor, fetal bovine serum, vascular endothelial growth factor, basic human fibroblast growth factor, recombinant human long R3 insulin-like growth factor 1, ascorbic acid, heparin, gentamicin, and amphotericin-B. Media was changed on culture day 4, and nonadherent bone marrow mononuclear cells were discarded, enriching for the EPC phenotype. A modified transwell migration assay (Boyden Chamber, Neuro Probe, Gaithersburg, MD) was used to assess EPC migration as previously described (see online-only Data Supplement for a detailed description). 23, 26, 27 Animal Model MI was induced in 36 adult male Dorset sheep (weighing between 35 and 45 kg) using an established and highly reproducible model. 32 Briefly, the animals were induced with intramuscular midazolam (0.4 mg/kg) and ketamine (5 mg/kg), and anesthesia was maintained on inhaled isoflurane (1.5%-3%). An anterior, 5 cm mini-thoracotomy was used to access the left chest cavity, and the heart was exposed. The distal left anterior descending and the second diagonal coronary arteries were ligated with a 4-0 polypropylene suture, creating an anteroapical area of ischemia ( Figure 1 ). Animals were randomized to receive either 1 mL of saline (n=18) or 6 μg/kg of ESA (n=18) diluted in 1 mL of saline injected via a custom-made 25-gauge end-capped needle (Cadence Inc, Staunton, VA) with 3 side holes each separated by 120° in 10 equal aliquots around the borderzone of the ischemic myocardium. The concentration of ESA administered was chosen based on dose response curves on which we have previously published. 26, 29 Continuous ECG monitoring was used throughout the procedure. All animals received an intramuscular injection of sargramostim (granulocyte-macrophage colony-stimulating factor, 40 μg/kg). Animals were recovered from anesthesia, and buprenorphine (0.05 mg/kg IM) along with a transdermal fentanyl patch (75 μg/h) was used for postoperative pain control. A total of 5 animals developed refractory ventricular fibrillation immediately after ligation (n=3 in the saline group, n=2 in the ESA group), and 1 animal in the saline group died during the follow-up period (autopsy revealed intestinal volvulus with resultant perforation). All surviving animals were euthanized 8 weeks after MI.
Cardiac MRI
A subset of animals (ESA, n=7; saline, n=5) underwent cardiac MRI before and 8 weeks after MI to assess global ventricular function, ventricular geometry, and 3D strain. General anesthesia was maintained for the entirety of the imaging procedures as described above. A high-fidelity pressure transduction catheter (Millar Instruments, Houston, TX) was inserted into the left ventricle (LV) via the carotid artery under fluoroscopic guidance for LV pressure gating during image acquisition. MRI was performed using a 3T MAGNETOM Verio scanner (Siemens, Malvern, PA) before infarction and 8 weeks after infarction as previously described (see 
MR Image Postprocessing
Treatment groups of the imaging data sets were blinded to the enduser throughout postprocessing. LV volume and global function data were obtained using prospective steady state free precession cine MR images. Raw short-axis images were automatically sorted, cropped, and contrast normalized in a custom Matlab (Natick, MA) program to ensure homogeneous LV coverage and image quality, respectively. Segmentation was then performed through all cardiac phases of the sorted and correct images using a semiautomated 3D active contour segmentation program (ITK-SNAP, open access/source). 34 LV end-diastolic volume, end-systolic volume, stroke volume, and ejection fraction (EF) were then computed throughout the entire cardiac cycle from segmented images using in-plane and through-plane spatial resolution information.
Systolic regional strain measurements from the borderzone were calculated from 3D spatial modulation of magnetization acquisitions using an optical flow technique as previously described ( Figure 2 ). 35 Maximum principle strain (ε 1 ) was then calculated for each region, and 3D strain maps were generated (see online-only Data Supplement for a detailed description).
Invasive Hemodynamic Assessment
Pressure-volume (PV) loops were acquired in all animals before infarction and 8 weeks after MI. A Ventri-Cath PV catheter transducer (Millar Instruments Inc, Houston, TX) was placed into the LV via the right carotid artery. Steady state PV loops were acquired during a 10-second breath hold, followed by inferior vena cava occlusion to produce static and dynamic loops under varying load conditions. Coronary angiograms were performed, and cardiac output was measured using periaortic Doppler flow probes (Transonic Systems, Ithaca, NY) (see online-only Data Supplement for a detailed description and Online Movie II for a representative coronary angiogram).
Histological Analysis and Immunohistochemistry
To assess ventricular geometry, infarct size, and microvascular angiogenesis, hearts were explanted after the invasive hemodynamic assessment was performed and flushed with saline. The atria were removed, and the LV opened along the posterior septum. Standardized digital photographs were taken with a Nikon D5100 SLR camera (Nikon, Tokyo, Japan). Photographs were uploaded to ImageJ (v1.46b) and the size of the infarct assessed with digital planimetry. Ventricular samples (3 cm 3 ) were taken from the infarct, borderzone, and remote myocardium, snap frozen in liquid nitrogen, and stored in a −80ºC freezer. Ten-micrometer-thick sections were prepared from each biopsy specimen.
Ten-micrometer-thick sections from the borderzone of each heart were stained with antibodies directed against von Willebrand Factor and separately for α-smooth muscle actin to quantify capillary and arteriolar density as previously described. A, SPAMM creates a periodic modulation of magnetization along a desired direction by applying a series of nonselective excitation pulses, creating tagged lines that move with the myocardium, providing a 3D sample of cardiac motion. This is a representative cross-sectional 3D SPAMM-tagged image of the left ventricle (LV), where 3 tag planes are used; 2 through plane tags and 1 oblique tag plane. Blood appears black, and the myocardium is bright. To measure systolic regional strain, the LV myocardium was contoured to create an image mask, and a custom optical flow plug-in for ImageJ was used to calculate x, y, and z displacement flow fields (B, C, and D, respectively).
mRNA was analyzed with a MMP profile (1, 2, 7, 8, 9, 12, 14) , TIMP profile (1, 2, 4), elastin, and transforming growth factor-β using QuantiGene 2.0 Plex Assay kit (Affymetrix) according to the manufacturer's protocol (see online-only Data Supplement for detailed description).
Ventricular ECM Protein Expression
Myocardial biopsies (10 mm 3 ) were removed from the LV at the time of explant (regions: infarct, borderzone, and remote) and snap frozen in liquid nitrogen. Samples were homogenized in T-PER protein extraction reagent along with HALT protease inhibitor (Thermo Scientific, Waltham MA). Final protein concentrations were determined using the Qubit protein assay (Qubit fluorometer, Life Technologies, Carlsbad CA). The extracellular membrane profile of each myocardial region was assessed via immunoblotting (see online-only Data Supplement for further details including specific antibodies used).
Statistical Analysis
All analyzed variables approximated a normal distribution, and values for continuous variables were reported as mean±SD. A 1-way ANOVA with Tukey correction was used for comparison of continuous variables between groups. Statistical significance was set at P<0.05. Analyses were performed with STATA (StataCorp, College Station, TX) statistical software package, version 12.1.
Results

ESA Induces Chemotaxis of Sheep EPCs
To confirm the efficacy of ESA in sheep, a transwell migration assay was used. EPCs showed significantly increased chemotaxis toward ESA compared with saline alone (saline, 97.3±4. Figure 3 ).
Differential Ventricular ECM mRNA Expression and Protein Concentration
Biopsies from the infarct, borderzone, and remote myocardium were taken for RNA analysis and assessed for MMP, TIMP, elastin, and transforming growth factor-β levels. RNA levels of MMP-2 were found to be elevated in the borderzone myocardium from sheep in the saline control group compared with the ESA group (saline, 0.1±0.01 ratio of fluorescence unit [RFU]; ESA, 0.03±0.01 RFU; P<0.05), whereas there was no difference in the other MMPs from any myocardial region between groups. Interestingly, RNA levels of TIMP-1 and elastin were elevated in the infarct of ESA-treated animals (TIMP-1; saline, 0.3±0.4 RFU; ESA, 2.4±1.0 RFU; P<0.05, elastin; saline, 0.3±0.2 RFU; ESA, 3.1±1.2 RFU; P<0.05). RNA expression profiles from all regions are presented in Figure 4 .
To determine whether the differential changes in MMP and TIMP mRNA expression between groups led to differences in protein concentration and were not undergoing alterations in post-transcriptional or post-translational modification events, immunoblots were performed. Results were consistent with the mRNA expression data, where protein levels of MMP-2 were elevated in the myocardium of sheep from the saline group compared with the ESA group (saline, 0.58±0.05; ESA, 0.074±0.037; P<0.05), with no differences in any of the other MMP protein levels between groups. Again, TIMP-1 and elastin protein concentrations were higher in the infarct region of myocardium from ESA-treated animals (TIMP-1; saline, 0.38±0.03; ESA, 0.73±0.18; P<0.05, elastin; saline, 0.17±0.04; ESA, 0.66±0.3; P<0.05). There were no significant differences among the other protein levels of myocardial regions between groups. Representative immunoblot results for MMP-2 (borderzone), TIMP-1 (infarct), and elastin (infarct) are presented in Figure 4 .
Microvascular Density and Myocardial Perfusion
Biopsies from the borderzone were sectioned and stained for von Willebrand Factor and α-smooth muscle actin. Analysis of immunofluorescently labeled von Willebrand Factor and α-smooth muscle actin showed a significant increase in both capillary and arteriolar density in the ESA group compared with the saline control (von Willebrand Factor: saline, 7.5±1. 4 Figure 5 .
To determine if the increased vascularity actually improved myocardial perfusion, coronary angiograms were performed and assessed for collateral filling using a previously validated method described by Rentrop et al. 36 Rentrop scores were calculated for each animal and averaged for each group. The saline group had significantly less collateral filling compared with the ESA group (saline, 0.5±0.7; ESA, 2.0±0.8; P<0.05) (see online-only Movie II for a representative coronary angiogram).
ESA Treatment Improves Regional Strain and LV Function While Limiting Remodeling
Maximal principle strain (ε 1 ) was measured in the borderzone region of animals treated with ESA and saline before and 8 weeks after MI. ε 1 is indicative of radial myocardial displacement, and the magnitude of in-plane displacement was depicted as a color map overlay ( Figure 6 ). Late gadolinium enhanced images were used for infarct identification and aided in choosing the appropriate regions of interest within the strain color maps. The composite strain data show that animals treated with ESA had significantly elevated ε 1 within the borderzone compared with saline control (saline, 8.8±3.3%; ESA, 12.4±5.8%; P<0.01), indicative of differential systolic stretching and radial wall thickening between groups. Because radial strain was measured, changes in the thickness of borderzone myocardium between systole and diastole could be evaluated, measures that correlate to regional contractility. Thus, the increased borderzone strain seen in hearts from animals in the ESA group is a result of improved and more efficient myocardial contraction compared with hearts from animals in the saline group.
Steady state free precession cine MR images were used to calculate EF, stroke volume, end-systolic volume, and end-diastolic volume for both treatment groups. At baseline, the EF was 46%, similar to previous studies using Dorset sheep. 37, 38 Eight weeks after infarction, animals in the saline group had a decline in EF to 27.8±4.9%, whereas animals in the ESA group had a relatively preserved EF of 36.4±6.4% (P=0.01). In addition, animals in the saline group had significantly larger endsystolic and end-diastolic volumes (end-systolic volume: saline, 96.5±21. LV systolic function was further assessed using a PV catheter transducer and aortic flow probe. The slope of the end-systolic PV relationship curve was derived from PV loops during inferior vena cava occlusion and represents end-systolic elastance, an approximation of myocardial contractility (see Figure 7 for representative PV loops). Animals in the ESA group had an elevation in the slope of the end-systolic PV relationship compared to animals in the saline group (saline, 1.6±0.07; ESA, 6.9±2.6; P=0.01), consistent with improved LV contractility. Furthermore, cardiac output, as measured by periaortic flow Representative color maps of hearts from engineered stromal cell-derived factor 1α analog (ESA)-treated animals show elevated (red on color map) regional strain about the borderzone. Hearts from saline-treated animals show decreased (green to blue) regional strain about the borderzone. Representative color map of a heart from a normal animal without myocardial infarction shows a characteristic strain pattern with elevated strain throughout the free wall of the LV. B, Cross-sectional late gadolinium enhanced MR images corresponding to the strain maps from the saline and ESA groups (white arrows delineate boundary of infarct; scar tissue shows up white from gadolinium contrast). C, Regional strain at the borderzone is significantly elevated in hearts from animals treated with ESA compared with hearts from animals treated with saline and closer to healthy myocardium (*P<0.05). . Analysis of immunofluorescent expression of vWF and αSMA revealed a significant increase in signal in the engineered stromal cell-derived factor 1α analog (ESA) group compared with saline (E and F, respectively). Coronary angiograms were reviewed and assessed for collateral filling using Rentrop scores in an effort to evaluate whether or not the increased vascularity seen from the immunohistochemical data resulted in increased myocardial perfusion. G, Coronary angiograms from animals in the ESA group had significantly higher Rentrop scores, and hence better collateral filling, compared with angiograms from animals in the saline group (*P<0.05; scale bar=75 μm). DAPI indicates 4',6-diamidino-2-phenylindole. February 14, 2014
probe assessment, was significantly higher in the ESA group compared with the saline group (saline, 2.8±0.8 L/min; ESA, 4.1±1.1 L/min; P=0.01). There was no difference in heart rate between groups. At the time of terminal surgery, after all invasive hemodynamic parameters were obtained, animals were euthanized with retrograde KCl injection, hearts were explanted, the LV was opened, and the infarct was outlined and photographed. Quantification of infarct size, measured as a percentage of total LV area, revealed a significant infarct reduction in the ESA group compared with the saline group (saline, 21±1.9%; ESA, 14±0.4%; P<0.01; Figure 8 ).
Discussion
In this study, we attempted to evaluate the efficacy of intramyocardial injection of the novel engineered peptide ESA in a large animal model of MI to demonstrate the translational potential of this peptide. Here, we have successfully shown that ESA treatment results in effective EPC chemotaxis, increased capillary density in the borderzone, elevated borderzone maximal principle strain, reduced LV remodeling, and improved LV dynamics in post-MI sheep. These data build on our initial experience with ESA in small animal models of MI, where similar findings were noted. 26, 27, 30 Initially, we attempted to show that ESA retained its chemokine effect on sheep EPCs because we had previously demonstrated its efficacy on only mouse and rat EPCs. The results from the transwell migration assay conclusively prove the ability of ESA to induce migration of sheep EPCs. This holds significant importance when evaluating capillary and arteriolar density between the ESA and saline groups because ESA localizes EPCs to the site of injury, initiating neovasculogenesis and creating new capillaries resulting in perfused arteriolar networks. The microrevascularization that takes place after ESA treatment allows for retention of the ECM, reduction of infarct spreading, and improved regional and global LV function.
To further understand the mechanism behind the attenuation of LV remodeling seen in the ESA group, we studied the transcriptional regulation of select MMPs/TIMPs by quantification of mRNA levels within different regions of the ventricle (infarct, borderzone, and remote) and further assessed myocardial samples for their protein concentrations, showing concordance between mRNA and protein expression. Other groups have clearly shown that MMPs are upregulated in the infarct and borderzone after MI (specifically MMP 1, 2, 13, and 14), whereas TIMPs are downregulated (specifically TIMP 1, 2, and 4) compared with levels found in Figure 7 . Hemodynamic assessment. Pressure-volume (PV) loops were obtained during inferior vena cava (IVC) occlusion for variable load data. A and B, Representative PV loops from animals in the saline group and engineered stromal cell-derived factor 1α analog (ESA) group. Note the increased slope of the end-systolic PV relationship (ESPVR; red line) in the ESA group, a preload independent measure of myocardial contractility. C, Before PV loop acquisition, a small upper midline laparotomy was performed, and the suprahepatic IVC was dissected free and encircled with a vessel loop. This is a representative image of complete IVC occlusion by gentle retraction on the vessel loop. D, Animals in the ESA group had improved ejection fraction (EF), lower end-systolic volume (ESV), and lower end-diastolic volume (EDV) compared with animals in the saline group, representing preserved LV function and limited LV remodeling (*P<0.05). SV indicates stroke volume. normal myocardium. [6] [7] [8] This regional and type specific alteration in the MMP/TIMP expression profile leads to dysfunctional alteration in LV geometry because of ECM breakdown and infarct expansion. Our findings of decreased expression of MMP-2 within the borderzone and increased expression of TIMP-1 within the infarct of ESA-treated animals compared with saline control provide causal support for the decreased infarct size and limited LV remodeling seen within the ESA group. We suspect that the chemotactic properties of ESA localize EPCs to and around the infarct, causing microrevascularization, leading to preservation of the ECM and differential expression of MMPs and TIMPs, respectively. This theoretical explanation is supported by a study showing increased TIMP-1 and TIMP-2 levels in vitro from secretion by CD34+ bone marrow progenitor cells. 39 It is also worth mentioning that elastin mRNA and protein levels within infarcted tissue were statistically higher in the ESA group, an additional finding that supports maintenance of ECM within the infarct. The benefits of increased elastin levels within an infarct, such as decreased remodeling and improvement in LV hemodynamics, has been published. 40, 41 A key innovation in the current study was the application of highly advanced postprocessing software for the calculation of regional strain relying on sophisticated 3D cardiac MRI tissue tagging technology using a 3D optical flow technique. This externally validated method has proven enormously useful in the ability to assess myocardial strain accurately in vivo, and with excellent in-plane and through-plane resolution, accurate quantification of regional strain is possible. Our results of increased regional strain in the borderzone of ESA-treated animals suggest that myocardium in this region is thicker at end systole, which may be indicative of improved regional contractility. This is an intriguing finding and one that we have hypothesized in the past, but until now we have been unable to definitively prove. 30 With increased borderzone strain, ESA-treated animals exhibited enhanced global LV contractility with a significant elevation in the slope of the end-systolic PV relationship along with greatly improved cardiac output. The beneficial effects ESA has on LV function after MI is likely multifactorial and begins with increased borderzone vascularity, which leads to limited expansion of the infarct and decreased LV remodeling. The preservation of regional strain within the borderzone and its effect on global LV function have important clinical implications for the use of ESA in the prevention of ischemic cardiomyopathy in patients with acute MI.
Limitations
One limitation of this study is that it was performed in an acute animal model of MI, where the treatment was given immediately after coronary artery ligation. Although this satisfies our question for how ESA interacts with bone marrow progenitor cells and the effects these cells have on the myocardium, the positive findings reported here may not be extrapolated to include the breadth of pathology seen in human subjects, as often times treatment modalities must be effective in the setting of chronic heart failure. Chronic postischemic changes in a typical patient with ischemic cardiomyopathy offer a complex problem to the investigator, where deleterious remodeling has already taken place and a diminutive stem cell supply must be overcome. However, as a proof of principle study and a starting point, we have demonstrated here that ESA is effective in a sheep model of MI. The infarct was outlined and photographed for quantification. Representative images of a heart from an animal in the saline group (A) and a heart from an animal in the engineered stromal cell-derived factor 1α analog (ESA)-treated group (B). C, Animals in the ESA group had significantly reduced surface area of the LV and smaller infarct sizes compared with animals in the saline group (*P<0.05). February 14, 2014
Conclusions
In summary, intramyocardial injection of ESA induces chemotaxis of EPCs resulting in microrevascularization of the myocardium, increases maximal principle strain in the borderzone, limits ventricular remodeling, and improves ventricular function. The findings presented here illustrate the efficacy of ESA therapy post-MI and provide substantial support for the translational potential of this novel peptide in the treatment of heart disease.
